GB Sciences, Inc. (GBLX)
- Previous Close
0.0063 - Open
0.0062 - Bid --
- Ask --
- Day's Range
0.0062 - 0.0064 - 52 Week Range
0.0062 - 0.0200 - Volume
20,951 - Avg. Volume
130,017 - Market Cap (intraday)
2.617M - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Jul 12, 2024 - Jul 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
www.gbsciences.comRecent News: GBLX
Performance Overview: GBLX
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GBLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GBLX
Valuation Measures
Market Cap
2.62M
Enterprise Value
4.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.15
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-67.21%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.03M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
17.46k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-323.45k